Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a yeast extract injection finally banish common warts?

NCT ID NCT05889845

Disease control Sponsor: Nielsen BioSciences, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether injections of Candin, a yeast extract, can clear common warts better than a placebo. 330 people aged 12 and older with 3 to 20 warts received injections every two weeks until their wart disappeared. The goal was to see if Candin leads to complete wart clearance and how long that takes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Candin (yeast extract injection)
What this could lead to
If it works, Candin could offer a new, non-invasive treatment option for stubborn common warts.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. Warts may not clear, or the effect may be small compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

330 people

The number who actually took part.

Started

Jan 2025

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 3, but not more than 20 common warts (Verruca vulgaris) * Willing to agree to use adequate contraception methods during the study Exclusion Criteria: * Systemic or localized diseases, conditions, or medications that could interfere with the assessment of safety or efficacy or that compromise immune function * Candin delayed type hypersensitivity reaction test wheal sized \< 5 mm or \> 25 mm at the Baseline Visit * History of keloid formation * Prior treatment of common warts with liquid nitrogen, carbon dioxide, electrodesiccation, laser, surgery, salicylic acid, etc., that, in the Investigator's opinion, does not exhibit complete healing from the treatment * Treatment with immunotherapy (e.g., diphenylcyclopropenone \[DPCP\], dinitrochlorobenzene \[DNCB\], or other), imiquimod, 5-fluorouracil, bleomycin, or podophyllin within 12 weeks of the Baseline Visit or during the study * Prior treatment with Candida albicans within 12 weeks of the Baseline Visit or during the study * Systemic treatment with an immunosuppressive drug during the study or in the 6 months or 5 half lives prior to the Baseline Visit or during the study (e.g., azathioprine, 6 mercaptopurine, methotrexate, infliximab, adalimumab, etanercept, systemic steroids \[topical or inhaled steroids are acceptable\]). * Use of cantharidin or an investigational agent or device within the 30 days prior to the Baseline Visit or during the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Common warts (verruca vulgaris) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

common wart

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Common warts (verruca vulgaris)

Contacts and locations

Locations

  • Advocare Berlin Medical Associates

    Berlin, New Jersey, 08009, United States

  • Arkansas Pediatric Clinic

    Bryant, Arkansas, 72022, United States

  • Austin Institute for Clinical Research

    Pflugerville, Texas, 78660, United States

  • Bryn Mawr Health Center

    Newtown Square, Pennsylvania, 19073, United States

  • Cahaba Dermatology

    Birmingham, Alabama, 35244, United States

  • DermResearch

    Austin, Texas, 78759, United States

  • Dermatology Clinic of Arkansas

    Hot Springs, Arkansas, 71913, United States

  • Hamzavi Dermatology

    Fort Gratiot, Michigan, 48059, United States

  • Integrated Dermatology of Newton-Brighton

    Brighton, Massachusetts, 02135, United States

  • Integrative Skin Research

    Sacramento, California, 95815, United States

  • Johnson Dermatology

    Fort Smith, Arkansas, 72916, United States

  • Kaminska Dermatology

    Chicago, Illinois, 60657, United States

  • Long Beach Research

    Long Beach, California, 90805, United States

  • Schlessinger MD

    Omaha, Nebraska, 68144, United States

  • Velocity Clinical Englewood

    Englewood, Colorado, 80110, United States

  • Velocity Clinical Hampton

    Hampton, Virginia, 23666, United States

  • Velocity Clinical La Mesa

    La Mesa, California, 91942, United States

  • Velocity Clinical Spartanburg

    Spartanburg, South Carolina, 29303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.